Responses of Serum Androgen and Insulin Resistance to Metformin and Pioglitazone in Obese, Insulin-Resistant Women with Polycystic Ovary Syndrome


Department of Endocrinology (C.O.-G., S.L., L.H., G.C., A.P.), Department of Sterility (P.A.), and Direction of Investigation (G.A.-T.), Instituto Nacional de Perinatología, 11000 México City, México

Severe insulin resistance is a key abnormality in obese women with polycystic ovary syndrome (PCOS). The purpose of this study was to evaluate whether pioglitazone decreases insulin resistance (IR) and hyperandrogenism to the same extent as metformin in obese women with PCOS who have not received any previous treatment. Fifty-two women with PCOS were randomly allocated to receive either pioglitazone (30 mg/d, n = 25) or metformin (850 mg three times daily, n = 27) and were assessed before and after 6 months. Body weight, body mass index, and waist to hip ratio increased significantly (P < 0.05) after pioglitazone treatment but not after metformin treatment. Fasting serum insulin concentration (P < 0.001 for both drugs) and the area under the insulin curve during a 2-h oral glucose tolerance test decreased after pioglitazone (P < 0.002) or metformin (P < 0.05) treatment. IR (homeostasis model of assessment-IR index) decreased and insulin sensitivity (elevation of the quantitative insulin sensitivity check index and the fasting glucose to insulin ratio) increased (P ≤ 0.008) after treatment with either drug. Hirsutism (P < 0.05) and serum concentrations of free testosterone (P < 0.02) and androstenedione (P < 0.01) declined to a similar extent after treatment with the drugs. Treatment with pioglitazone or metformin was associated with the occurrence of pregnancy (n = 5 and n = 3, respectively). These results suggest that pioglitazone is as effective as metformin in improving insulin sensitivity and hyperandrogenism, despite an increase in body weight, body mass index, and the waist to hip ratio associated with pioglitazone. (J Clin Endocrinol Metab 90: 1360–1365, 2005)

Subjects and Methods

The study protocol was approved by the Internal Review Board and the Human Ethical Committee of the Instituto Nacional de Perinatología.
hydroxyprogesterone, and cortisol) on d 3–5 of a spontaneous menstrual cycle. The diagnosis of PCOS was based on at least two of the three following abnormalities: oligomenorrhea or anovulation, a serum androstenedione concentration more than 2.9 ng/ml (>10.1 nm), or a serum free testosterone (T) concentration more than 2.5 pg/ml (>8.6 pm) and polycystic ovaries by ultrasound (2). All women had a body mass index (BMI) ≥25 kg/m², acanthosis nigricans, fasting hyperinsulinemia greater than 16 mU/ml (>114.8 pm), and a fasting glucose to insulin ratio of less than 4.5 (26). The presence of the following disorders was excluded by specific laboratory tests: impaired glucose tolerance test or type 2 DM, hyperprolactinemia, thyroid disorders, late-onset congenital adrenal hyperplasia, and Cushing’s syndrome. None of the women had been taking clomiphene citrate, oral contraceptives, antiandrogens, or drugs to control their appetite during the previous 6 months. We confirmed the absence of unsuspected pregnancy in all participants before including them in the study. Criteria for exclusion during the study included diagnosis of pregnancy, loss to follow-up, and increased concentration of serum transaminases.

**Study design**

Treatments. Patients were randomly allocated to one of the following two groups: group 1 (n = 25) received pioglitazone (Zactos; Eli Lilly de México, S.A. de C.V., México City, México) 30 mg/d in an oral single dose for 24 wk, and group 2 (n = 27) received metformin (Fisonax; Fisa Farmacéutica de México, S.A. de C.V., México City, México) orally administered at a dose of 850 mg three times daily for 24 wk. Randomization was by random number tables. The patients’ number treatment codes were retained until the end of the study in a sealed envelope by a third party who did not participate in the study; patients’ names were disclosed after completion of the study. Because the drugs had different daily dose schedules (i.e., once a day for pioglitazone and three times a day for metformin), the study had an open design. All women were on an unrestricted diet and were instructed not to modify their usual eating or physical exercise patterns during the study period. Subjects began taking the drugs 2 wk after written consent was obtained, and the results of the basal (metabolic and hormonal) studies were available. The women were given extensive contraceptive counseling and were carefully instructed to stop taking the drug immediately upon confirmation of pregnancy (quantitative serum β-human chorionic gonadotropin by RIA).

Assessment program. All patients underwent clinical, metabolic, and hormonal evaluations at baseline that included height, weight, BMI, waist to hip ratio, and hirsutism (F-G) score (29). In the baseline study, vaginal bleeding was induced by progesterone withdrawal, and the following studies were performed on d 3–5: After a 12-h overnight fast, a non-heparinized venous blood sample was obtained between 0800 and 0830 h to measure the circulating concentrations of prolactin (PRL), total T, glucose, total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and liver function tests, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase. Immediately after the basal blood sample was obtained, a 2-h oral glucose tolerance test (OGTT) was performed with an oral glucose load of 75 g, and nonheparinized blood samples were obtained after 30, 60, 90, and 120 min to measure serum glucose and insulin concentrations. At the end of month 6 of the treatment, the same clinical, metabolic, and hormonal evaluations were performed (except for the thyroid function tests and measurements of serum concentrations of PRL, dehydroepiandrosterone sulfate, 17α-

Role of the pharmaceutical companies providing the drugs under study

The pharmaceutical companies providing the drugs played no role in the study design, data collection, data analysis, data interpretation, or writing of the report. No funding of any kind was received to perform the study or by any of the participants in the study. None of the authors has any type of collaboration or working position in any of the drug companies.

**Statistical analysis**

All data are presented as mean ± SEM, unless stated otherwise. Descriptive statistics were used for continuous data at each visit. Changes in parameters over time were assessed using repeated measures ANOVA, and differences between groups were evaluated using a nonparametric test (Mann-Whitney). Within-group differences were analyzed by the paired Student’s t test. P < 0.05 was considered significant. Data analysis was performed using the statistical software package SPSS for Windows (SPSS, Inc., Chicago, IL).

**Results**

Clinical characteristics and compliance of the patients

Figure 1 shows the randomization of patients at the start of the study and data on subject retention to the end of the

Methods

The waist and hip circumferences were measured to the nearest centimeter with a soft tape measure according to the World Health Organization criteria. BMI was calculated using the following equation: weight (kg)/height (m²). Hirsutism was clinically evaluated using the F-G score obtained by the same observer (C.O.-G.); a score of greater than 8 was defined as hirsutism (29).

**Assay methods**

Hormone concentrations were determined in duplicate, and in each assay, the samples were distributed equally relative to each group to minimize the effect of intra- and interassay variability. Concentrations of FSH, LH, TSH, and PRL were analyzed using commercially available immunoradiometric kits (Diagnostic Products Corp., Los Angeles, CA); the intra- and interassay coefficients of variation were ≤6% and ≤7.8%, respectively. The concentrations of the other hormones were measured using commercially available RIA kits (Diagnostic Products Corporation); the intra- and interassay coefficients of variation were ≤8% and ≤9.2%, respectively. Using the serum glucose and insulin concentrations during fasting and the 2-h OGTT, we calculated the following parameters: homeostasis model of assessment (HOMA)-IR (30, 31) = fasting serum insulin (mU/ml) × fasting serum glucose (mmol/liter)/22.5; quantitative insulin sensitivity check index (QUICKI) (31, 32) = 1/[log (I0) + log (G0)], where I0 = fasting serum insulin (mU/ml) concentration and G0 = fasting serum glucose (mg/dl) concentration; β-cell function index (20) = 20 × [fasting serum insulin (mU/ml) concentration/fasting serum glucose concentration (mmol/liter)] − 3.5; fasting glucose to insulin ratio (4, 28) = fasting serum glucose concentration (mg/dl)/fasting serum insulin concentration (μU/ml); and area under the glucose curve (AUC-glucose) and area under the insulin curve (AUC-insulin) using a trapezoidal method (33).

Serum TC, TG, HDL, and LDL cholesterol, ALT, AST, and alkaline phosphatase were measured using an automated spectrophotometer (Hitachi-912; Roche Mexico, México City, México). The interassay coefficient of variation was ≤3.9%.
6 months of treatment with either pioglitazone or metformin. In the pioglitazone group, three women were lost to follow-up, and five became pregnant; in the metformin group, two women were lost to follow-up, four abandoned the study because of severe gastrointestinal side effects, and three became pregnant. The clinical, metabolic, and hormonal measures at the baseline evaluation did not differ significantly between women lost to follow-up or the women who became pregnant and the remaining 35 women who completed the study. The five women lost to follow-up left the study for socioeconomic reasons. The final numbers of patients were 17 in the pioglitazone group and 18 in the metformin group, and the statistical analysis was performed on data from these 35 women only.

Table 1 presents the subjects’ clinical characteristics at baseline and after 6 months of treatment. There were no significant differences in clinical baseline characteristics between groups 1 and 2, and their ages were comparable. All subjects were overweight (BMI ≥ 28 kg/m²), had waist to hip ratios of more than 0.80, and had considerable hirsutism with F-G scores ≥ 10. After 6 months of treatment with pioglitazone, body weight increased by 4.7 kg and BMI increased (both \( P < 0.05 \)); treatment with metformin caused nonsignificant decreases in body weight and BMI. The waist to hip

<table>
<thead>
<tr>
<th>TABLE 1. Clinical characteristics of the patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parameter</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Age (yr)</td>
</tr>
<tr>
<td>Weight (kg)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
</tr>
<tr>
<td>W/H ratio</td>
</tr>
<tr>
<td>Hirsutism, F-G score</td>
</tr>
</tbody>
</table>

Values are mean ± SEM. W/H ratio, Waist to hip ratio.

<sup>a</sup> \( P < 0.05 \) compared with baseline.

<sup>b</sup> \( P = 0.02 \) compared with baseline.

<sup>c</sup> \( P < 0.001 \) compared with baseline.
ratio increased significantly ($P = 0.02$) after pioglitazone treatment and remained unchanged after metformin treatment. The F-G score decreased from baseline values in both groups.

**Metabolic parameters**

Table 2 presents the subjects’ metabolic parameters. None of the women had any degree of glucose intolerance at baseline because this was a criterion for exclusion from the study. At baseline, the metabolic parameters were comparable in both groups, which had clear hyperinsulinemia during both fasting and in response to the oral glucose challenge as indicated by the AUC-insulin. The baseline HOMA-IR index was elevated, whereas QUICKI and the fasting glucose to insulin ratio were similarly low in both groups.

The AUC-glucose decreased significantly after treatment with either drug ($P = 0.05$). Treatment with pioglitazone resulted in significant decreases in fasting serum insulin concentration ($P < 0.001$), the AUC-insulin during the 2-h OGTT ($P < 0.002$), and the HOMA-IR index ($P < 0.001$). Pioglitazone treatment increased the QUICKI ($P < 0.001$) and the fasting glucose to insulin ratio ($P < 0.001$). Treatment with metformin decreased fasting serum insulin concentration ($P < 0.001$), the AUC-insulin ($P < 0.05$), and the HOMA-IR index ($P < 0.001$). Metformin treatment increased significantly the QUICKI ($P < 0.008$) and the fasting glucose to insulin ratio ($P < 0.001$). After 6 months of treatment, the AUC-insulin was significantly lower in the pioglitazone group compared with the metformin group ($P < 0.05$).

Serum concentrations of TG, TC, HDL and LDL cholesterol, AST, and ALT were within the normal ranges at baseline in both groups and remained unchanged during the study, except for a slight decrease in serum TG concentration ($P = 0.05$) in the metformin group.

**Hormonal parameters**

Table 3 presents the hormonal parameters. The baseline hormone concentrations were similar in both groups. Pioglitazone and metformin had similar effects on androgen serum concentrations, causing significant decreases in the concentrations of free T ($P < 0.02$ and $P < 0.05$, respectively) and androstenedione (both $P < 0.01$). Serum LH concentrations decreased slightly but significantly in both groups ($P < 0.05$). The concentrations of the other hormones remained unchanged throughout the study in both groups.

**Pregnancy occurrence and outcomes**

Although we did not precisely evaluate ovulation rates, the occurrence of eight pregnancies during month 6 of administration of the drugs (five pregnancies on pioglitazone and three on metformin) suggests that these drugs induced rapid normalization of menstrual cycles and ovulation in a subset of these women. This is supported by significant increases in serum progesterone concentrations from 1.6 ± 0.4 ng/ml (5.0 ± 1.2 nm) to 4.5 ± 0.7 ng/ml (14.3 ± 2.2 nm) in the pioglitazone group ($P < 0.04$) and from 1.4 ± 0.7 ng/ml (4.4 ± 2.2 nm) to 4.1 ± 0.3 ng/ml (13.0 ± 1.0 nm) in the metformin group ($P < 0.05$). In our laboratory, a serum progesterone concentration greater than 3.5 ng/ml (11.1 nm) is indicative of ovulation. Of the eight women who became pregnant, four had a first-trimester abortion (three women on pioglitazone and one on metformin), and three developed gestational DM (two women on pioglitazone and one on metformin), which was treated with dietary management and insulin administration (twice a day), and subsequently had an uneventful at-term delivery (>38 wk of gestation). Only one woman (on metformin) had a full-term normal pregnancy. All four newborns (two from mothers on each drug) had a normal weight for gestational age and were clinically healthy and without perinatal complications.

**Discussion**

Our study showed that 6 months of administration of pioglitazone to obese women with PCOS and severe IR was as effective as metformin in decreasing fasting blood serum insulin concentration and the AUC-insulin during a 2-h OGTT without significantly changing fasting blood glucose concentration or the AUC-glucose. Pioglitazone and metformin caused similar significant decreases in hirsutism and

**TABLE 2. Metabolic parameters**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Baseline (n = 17)</th>
<th>6 Months (n = 17)</th>
<th>Baseline (n = 18)</th>
<th>6 Months (n = 18)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting glucose (mg/dl)</td>
<td>92.5 ± 2.6</td>
<td>88.6 ± 1.8</td>
<td>93.4 ± 2.9</td>
<td>88.7 ± 2.1</td>
</tr>
<tr>
<td>AUC-glucose (mg/dl/min)</td>
<td>16,383 ± 742</td>
<td>14,871 ± 734&lt;sup&gt;a&lt;/sup&gt;</td>
<td>17,337 ± 716</td>
<td>14,213 ± 684&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Fasting insulin (µU/ml)</td>
<td>31.1 ± 1.1</td>
<td>11.1 ± 1.4&lt;sup&gt;b,c&lt;/sup&gt;</td>
<td>31.1 ± 1.5</td>
<td>11.0 ± 1.4&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>AUC-insulin (µU/ml/min)</td>
<td>14,884 ± 1,800</td>
<td>10,830 ± 1,241&lt;sup&gt;b&lt;/sup&gt;</td>
<td>16,027 ± 2,078</td>
<td>13,415 ± 1,830&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>7.03 ± 0.28</td>
<td>2.42 ± 0.31&lt;sup&gt;b&lt;/sup&gt;</td>
<td>7.21 ± 0.52</td>
<td>2.43 ± 0.3&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>QUICKI</td>
<td>0.29 ± 0.001</td>
<td>0.34 ± 0.004&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.29 ± 0.001</td>
<td>0.34 ± 0.003&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Fasting G/I ratio</td>
<td>3.02 ± 0.13</td>
<td>9.38 ± 1.12&lt;sup&gt;b&lt;/sup&gt;</td>
<td>3.19 ± 0.13</td>
<td>9.33 ± 1.32&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Serum TG (mg/dl)</td>
<td>158.6 ± 14.8</td>
<td>143.7 ± 14.4</td>
<td>151.4 ± 11.0</td>
<td>124.6 ± 8.96&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>TC (mg/dl)</td>
<td>189.4 ± 7.7</td>
<td>174.3 ± 7.6</td>
<td>183.1 ± 6.3</td>
<td>181.3 ± 7.3</td>
</tr>
<tr>
<td>HDL cholesterol (mg/dl)</td>
<td>41.1 ± 2.1</td>
<td>46.9 ± 2.0</td>
<td>38.7 ± 2.5</td>
<td>42.6 ± 1.9</td>
</tr>
<tr>
<td>LDL cholesterol (mg/dl)</td>
<td>120.5 ± 6.2</td>
<td>116.1 ± 5.8</td>
<td>111.3 ± 5.6</td>
<td>124.3 ± 6.3</td>
</tr>
<tr>
<td>AST (IU/liter)</td>
<td>20.35 ± 1.34</td>
<td>18.00 ± 1.57</td>
<td>21.78 ± 1.90</td>
<td>23.10 ± 1.68</td>
</tr>
<tr>
<td>ALT (IU/liter)</td>
<td>22.65 ± 1.31</td>
<td>19.90 ± 1.22</td>
<td>26.06 ± 2.50</td>
<td>24.33 ± 1.98</td>
</tr>
</tbody>
</table>

Values are means ± SEM. Conversion factors: glucose, 0.05551; insulin, 7.175; TG, 0.01129; TC, 0.02586; HDL cholesterol, 0.02586; LDL cholesterol, 0.02586; AST, 1.0; ALT, 1.0. G/I, Glucose to insulin.

<sup>a</sup> $P = 0.05$ compared with baseline values of the corresponding group.

<sup>b</sup> $P < 0.008$ compared with baseline values of the corresponding group.

<sup>c</sup> $P < 0.05$ compared with the metformin group at 6 months.
Hormonal parameters

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Pioglitazone</th>
<th>Metformin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline (n = 17)</td>
<td>6 Months (n = 17)</td>
</tr>
<tr>
<td>DHEAS (µg/dl)</td>
<td>248.7 ± 33.6</td>
<td>221.3 ± 33.8</td>
</tr>
<tr>
<td>Free T (pg/ml)</td>
<td>3.07 ± 0.39</td>
<td>2.12 ± 0.35*</td>
</tr>
<tr>
<td>Androstenedione (ng/ml)</td>
<td>3.81 ± 0.32</td>
<td>2.50 ± 0.26*</td>
</tr>
<tr>
<td>LH (ng/ml)</td>
<td>4.53 ± 0.46</td>
<td>3.08 ± 0.29*</td>
</tr>
<tr>
<td>FSH (mIU/ml)</td>
<td>4.13 ± 0.40</td>
<td>4.68 ± 0.73</td>
</tr>
<tr>
<td>Estradiol (pg/ml)</td>
<td>51.29 ± 6.84</td>
<td>37.52 ± 4.20</td>
</tr>
</tbody>
</table>

Values are means ± SEM. Conversion factors: DHEAS, 0.002714; free T, 3.467; androstenedione, 3.492; LH, 1.0; FSH, 1.0; estradiol, 3.671. DHEAS, Dehydroepiandrosterone sulfate.

* P < 0.05 compared with baseline value in the same group.

Two points deserve comment. First, because we selected only markedly obese PCOS women with acanthosis nigricans and the most advance degree of IR, our results may not apply strictly to all women with PCOS. Second, the reported values of free T were obtained using a competitive RIA test, which is less reliable than those obtained by calculating the free androgen index.

Our results agree with previous reports using other TZDs (22, 24) or metformin (6, 17, 19) and with recent studies in obese women with PCOS and IR taking either pioglitazone (25–27) or metformin (15, 17, 34). However, in our head-to-head trial with metformin, pioglitazone seemed to be more effective in improving insulin sensitivity because both fasting serum insulin concentration and the AUC-insulin were significantly lower after pioglitazone than after metformin treatment. The same observation has been reported recently in patients with type 2 DM (35). This is particularly interesting because, in our study, a submaximal dose of pioglitazone was given (maximum dose recommended for treatment of DM is 45 mg/d), whereas metformin was given in the maximal dose (2.5 g/d).

Recent data suggest that the amelioration of clinical and hormonal hyperandrogenism induced by specific treatment in women with PCOS could be jeopardized by an increase in body weight and BMI (36). However, we found that both drugs caused similar improvements in clinical and hormonal hyperandrogenism and that pioglitazone was more effective in reducing IR and improving the indices of insulin sensitivity. These changes occurred despite a significant increase in body weight, BMI, and waist to hip ratio associated with the use of pioglitazone but not with metformin. Similar findings have been reported in obese male and female patients with type 2 DM and IR treated with other TZDs (35–37). These paradoxical results can be explained by the beneficial shift from abdominal to sc fat and the simultaneous improvement in insulin sensitivity induced by TZD (37–39).

Pioglitazone may improve hyperandrogenism through a similar mechanism as troglitazone. The putative ligand-mediated activation of PPARγ2 by troglitazone impairs androgen and stimulates progesterone biosynthesis in primary cultures of porcine theca cells (40) by blocking the expression of the cytochrome P450–17α hydroxylase/C17–20 lyase gene and cytochrome P450 protein phosphorylation, which decreases the LH-insulin-driven theca cell androgen production (41).

Obese women with PCOS may demonstrate higher intra- and interindividual variation in the IR calculated using the HOMA method than obese control women without PCOS (42). It has been proposed that, at any level of IR, a decline by more than 31% is needed in a subsequent sample to ascribe any change to a therapeutic intervention (42). We found decreases of 66% and 67% in the HOMA-IR index after 6 months of treatment with pioglitazone and metformin, respectively, and decreases of 59% and 40% in fasting serum insulin concentration after treatment with pioglitazone and metformin, respectively. These changes suggest that the amelioration of the IR status in these obese women with PCOS can be attributed to the effects of pioglitazone or metformin.

Pregnancy events and complications (e.g. abortions and gestational DM) seemed to occur more frequently in the pioglitazone than in the metformin group, although the sample size is too small to draw any final conclusions. We believe that it is necessary to comment on the safety of TZD and metformin in women who may become pregnant, such as those in our study. Pioglitazone and rosiglitazone are classified as pregnancy category C drugs because of animal evidence showing growth retardation in mid to late gestation. Thus, women with PCOS being treated with either drug should be given extensive contraceptive counseling at the onset and carefully instructed to stop taking the drug immediately if pregnancy be confirmed (43, 44). This contrasts markedly with metformin, which is classified as a pregnancy category B drug and which appears to be safe during pregnancy for mother and fetus and even seems to reduce the risk of first-trimester abortion (45, 46).

In summary, our head-to-head study demonstrated that administration of pioglitazone for 6 months was as effective as metformin in improving severe IR and hyperandrogenism in obese women with PCOS. Pioglitazone, but not metformin, caused a simultaneous increase in body weight, BMI, and the waist to hip ratio. Pioglitazone was not hepatotoxic and did not cause substantial side effects. Further studies are needed to measure the effects of pioglitazone on fat tissue metabolism, the distribution of visceral and sc fat, and IR in obese women with PCOS. Pioglitazone’s potential therapeutic value of promoting a beneficial shift from abdominal to sc fat may outweigh the increase in body weight and BMI and perhaps total body fat level.
We express our gratitude to all volunteers who participated in the study. We are also indebted to Eli Lilly de México, S.A. de C.V., and to PISA Farmacéutica de México, S.A. de C.V., for the unconditional supply of pioglitazone and metformin, respectively.

Received October 7, 2004. Accepted December 6, 2004.

Address all correspondence and requests for reprints to: C. Ortega-González, M.D., Instituto Nacional de Perinatología, Department of Endocrinology, Montes Urales 800, Lomas Vireyes, 11000 México City, México. E-mail: ortegacarlos@hotmail.com.

References

1. Lobo RA 2003 What are the key features of importance in polycystic ovary syndrome? Fertil Steril 80:259 –261


7. Nestler JE, Jakubowicz DJ, de Vargas AF, Brik C, Quintero N, Medina F 1998 Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 83:2001–2005


18. Hattersley TA, Carr BR, Attia GR 2003 Effects of metformin on body mass index, menstrual cyclicity, and ovulation induction in women with polycystic ovary syndrome. Fertil Steril 79:469–481

19. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ 1994 Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenism, and systolic blood pressure, while facilitating menstrual cyclicity, and ovulation induction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 83:3299–3306


24. Bremmthalter N, De Geyter C, Huber PR, Keller U 2004 Effect of the insulin sensitizing agent pioglitazone on insulin resistance, hyperandrogenism and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 89:3835–3840


28. Tai MM 1994 A mathematical model for the determination of total area under glucose tolerance and other metabolic curves. Diabetes Care 17:152–154


JCEM is published monthly by The Endocrine Society (http://www.endo-society.org), the foremost professional society serving the community.